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Abstract
Alzheimer’s disease (AD) is characterized by two molecular pathologies:
cerebral beta-amyloidosis (amyloid-beta [Aβ] plaques) and tauopathy
(neurofibrillary tangles, neuritic plaques and neuropil threads). Until recently, only
Aβ topographies could be studied in vivo in humans owing to a lack of tau positron
emission tomography (PET) imaging agents. Current clinic-pathological studies link
tau pathology closely to the onset and progression of cognitive symptoms AD. This
study reports on PET tau and Aβ imaging results in a cohort of cognitively normal
older adults and those with very mild AD. Multivariate analyses identified unique
disease-related spatial topographies in both tau and Aβ deposition. These PET tau
and Aβ topographies were spatially unique but strongly related. Cerebrospinal fluid
measures of tau, often used to stage preclinical AD, were strongly correlated with
tau deposition in the temporal lobe. Tau deposition in the temporal lobe more
closely tracked dementia status and was a better predictor of cognitive performance
than Aβ deposition in any region of the brain. These data support models of AD
where tau pathology closely tracks changes in brain function responsible for the
onset of early symptoms.

Introduction
Alzheimer’s disease (AD) is characterized neuropathologically by the
presence of amyloid-beta (Aβ) plaques and tau-immunoreactive neuritic plaques,
neurofibrillary tangles and neuropil threads in the cerebral cortex (1). Autopsy
studies demonstrate that Aβ and tau pathology accumulate in stereotypical spatial

patterns, or topographies, over the course of the disease (2, 3). Topographic studies
of AD-related pathology in vivo, until recently, have been limited to fibrillar Aβ (4, 5)
owing to a lack of positron emission tomography (PET) tau pathology imaging
agents. However, a number of tau pathology imaging agents have recently been
developed and are available for human studies (6).

Extant models of AD pathophysiology establish a temporal ordering of
biomarkers, with the emergence of AD-related tauopathy occurring downstream to
the accrual of Aβ pathology (7-11). Consistent with this proposal, markers of tau
pathology correlate more closely with changes in cognition compared to
Aβ measures (12). However, the prior lack of imaging agents has limited studies of
tau to post-mortem examinations (13-16) or measures that lack topographic
information (i.e., cerebrospinal fluid [CSF]). As a result, relationships between
cognition and Aβ topography have been defined (17), but the relationship with tau
topography is not defined in vivo. Without this spatial information, CSF tau
measures may be assessing other forms of neurodegeneration related to cell death
or synaptic dysfunction.

The use of both tau and Aβ imaging allows for the attribution of AD-related
cognitive dysfunction to specific pathological process and locations within the brain.
Further, the spatial relationships between tau pathology and other biomarkers of
AD are not established. This report examines how tau imaging topographies relate
to clinical status, Aβ imaging, CSF measures of AD pathology, and

neuropsychological performance. Tau and Aβ represent distinct pathological
processes but they are strongly related in the context of AD. Given that PET- and
CSF-based techniques may measure similar processes (18), PET and CSF
measurements of tau and Aβ are hypothesized to be related but that relationship is
likely stronger within specific topographies. Next, the relationship between tau and
Aβ imaging with cognition was assessed. Given extant models (8, 9) and limited
autopsy-based empirical data (13-15) it was hypothesized that tau would be a
stronger predictor of cognition than Aβ owing to its place later in preclinical disease
course. These relationships are investigated in vivo for the first time using
multivariate statistical models well suited to identify PET topographies associated
with presence or absence of disease, identify relationships between Aβ and tau
pathology in distinct topographies, and describe the relationship with CSF and
neuropsychological measures of disease.

Results
Data from forty-six individuals was examined. Global cognitive and
functional performance was assessed by the clinical dementia rating (CDR) (19).
Each participant underwent T807 (tau) (20) and florbetapir (Aβ) positron emission
tomography (PET) and magnetic resonance imaging (MRI). A subset also underwent
lumbar puncture for CSF assays and/or neuropsychological testing. Demographics
of each subset of the cohort are provided in Table 1. Standardized uptake value
ratios (SUVR) with (when presenting regional data) and without (when presenting
voxelwise data) partial volume correction were calculated within 42 bilateral

anatomical regions of interest (ROI) defined by FreeSurfer (21, 22). For additional
methodological detail throughout, see Methods and Supplemental Material.

Clinically Impaired Participants Demonstrate Elevated Tau Burden
Mean (across participants) tau and Aβ SUVR images are shown in Figure 1;
representative single subject data are shown in Supplemental Figure 1. The data
were split into two groups based on the presence or absence of cognitive
impairment. Cognitively normal (CDR 0; 𝑁 = 36) participants show minimal tau
tracer uptake throughout the brain with the exception of the basal ganglia.
Cognitively impaired (CDR>0; 𝑁 = 10) participants exhibited markedly increased
uptake in the temporal lobes and throughout the cortex. The Aβ images demonstrate
the known separation between cognitively normal and cognitively impaired groups.

Distinct Tau and Aβ Topographies are Associated with Cognitive Impairment
To assess the behavior of PET tau and Aβ pathology across participants, the
imaging data were first decomposed into component topographies. This
accomplishes two goals: 1) accounts for the correlation structure of the data across
ROIs and 2) reduces the number of statistical comparisons. Thus, singular value
decomposition (SVD) identifies a small number of latent component topographies
whose representation in single subjects explains a majority of the variance. In each
participant, PET tau and Aβ pathology burden was assessed in 42 ROIs, however,
many ROIs are highly correlated and can be more concisely summarized as
topographies, or combinations, of ROIs. The PET tau and Aβ data were arranged into

participant (N=46) by ROI (M=42) matrices separately and subjected to SVD. PET
tau and Aβ each were best described as a combination of two component
topographies (Figure 2A). Both PET tau and Aβ demonstrated empirically
determined rank 2 suggesting that the two biomarkers have similar signal to noise
characteristics. For both PET tau and Aβ, the first topography roughly corresponded
to the mean of the image (i.e., regions are similarly positively weighted). The second
PET tau topography was most strongly loaded in the temporal lobe including the
hippocampus. In contrast, the second PET Aβ topography was most strongly loaded
in frontal and parietal regions. This analysis demonstrates that both PET tau and Aβ
data exhibit strong autocorrelation across ROIs but each has distinct topographies.

In each participant, the representation of each of the 2 PET tau and 2 PET Aβ
topographies described above was best estimated using regional weights derived
from the SVD. For each topography, these values were subjected to an ANCOVA with
age, CDR, and presence of an apolipoprotein (APOE ) ε4 allele as factors
(Supplemental Table 1). The two PET tau topographies were more strongly
represented in participants with higher CDR status (p < 0.001) but were not
significantly modified by age or APOE status (Figure 2B). The first PET Aβ
topography was not significantly associated with any variables of interest, however
the second topography was more strongly represented in participants with higher
CDR status (p = 0.04) and moderately associated with increasing age (p = 0.08). In
both the tau and Aβ data there are statistically significant differences between the
CDR 0 and CDR>0 groups, however there is significant overlap particularly in the Aβ

result. The separation between the CDR 0 and CDR>0 groups was more marked in
the PET tau data compared to the PET Aβ data. This visual observation is quantified
as F values that are an order of magnitude larger for PET tau compared to PET Aβ
(Supplemental Table 1). Thus, as measured by the CDR, representation of tau
topographies more strongly associates with dementia status across participants.

Evidence of Preclinical AD is Associated with Pathological Topographies
Inspection of Figure 2B reveals that expression of the each topography varies
widely in the CDR 0 participants, particularly with respect to PET Aβ topographies.
CDR 0 implies cognitive normality but not absence of preclinical pathology.
Preclinical AD can be operationalized using CSF measures of tau and Aβ with simple
scalar cutoffs. To most simply characterize the pathological status of the CDR 0
participants, median splits were used to dichotomize participants as either CSF Aβ±
or tau±. Aβ–, tau– corresponds to healthy aging without pathology; Aβ+,tau–
corresponds to Stage 1 preclinical disease; Aβ+, tau+ corresponds to Stage 2
preclinical disease (23, 24). Stratifying CDR 0 participants in this manner reveals
that CDR 0 participants with higher expression of the component topographies tend
to have CSF evidence of elevated Aβ or tau pathology (Figure 2C). The effect of
preclinical disease stage is more marked on PET Aβ, suggesting that tau pathology
burden is more closely temporally linked to clinical status as measured by CDR and
preclinical disease stage. The preceding results were reproduced in a larger sample
who only had PET tau data available (See Supplemental Results).

PET Tau and Aβ, in Distinct Topographies, are Strongly Correlated
The previous analysis described the relationship between PET tau and Aβ
topographies and disease stage. Next, the relationship between the PET tau and Aβ
topographies was compared directly using canonical correlation. Canonical
correlation is a multivariate generalization of the more familiar bivariate
correlation. Canonical correlation identifies both a PET tau and PET Aβ topography
such that the data, when projected onto these weighted topographies, are maximally
correlated. Thus, canonical correlation identifies the topography of each
pathological species that is most related to the other species. The present PET tau
and Aβ topographies were represented by a single canonical correlation that
explained 75% of the covariance in the data (Figure 3). The weighted regional
patterns of the two topographies were modestly correlated (r = 0.29, p = 0.062),
which reflects the known divergence in the pathologic topographies (2, 3). The PET
data weighted and averaged according to these topographies were highly correlated
(r = 0.92, p < 10–18), which reflects the strong relationship between tau and Aβ when
the appropriate topographies are considered. The PET tau topography that was
most heavily loaded in medial temporal lobe, parietal cortex, and precuneus and
was most highly correlated with PET Aβ topography in the frontal and parietal
regions.

Mean PET tau and Aβ are Correlated with CSF tau, p-tau, and Aβ42
PET tau and Aβ imaging techniques and CSF based techniques may measure
correlated pathological processes (18). Therefore, the two measures may be related.

To investigate this relationship, the correlations between mean (calculated across
all grey matter regions) PET tau and Aβ and CSF tau, phosphorylated tau (p-tau),
and Aβ42 were calculated (Supplemental Table 2). As predicted, mean PET tau was
positively correlated with CSF tau (r = 0.36, p = 0.029) and CSF p-tau (r = 0.29, p =
0.089) but was not significantly correlated with CSF Aβ42 (r = –0.25, p = 0.14); mean
PET Aβ was negatively correlated with CSF Aβ42 (r = –0.54, p = 0.006) but also
positively correlated with CSF tau (r = 0.52, p = 0.0011) and p-tau (r = 0.49, p =
0.0023). The negative correlations owe to CSF Aβ42 being reduced, not increased, by
the AD process as more Aβ becomes deposited in the brain. Therefore, the PET and
CSF techniques are strongly correlated measures of AD pathological processes.
However, the strengths of these relationships were not remarkably strong and vary
across biomarkers. The limited strength of these correlations may owe to the PET ~
CSF relationship only being strong within particular topographies; that topographic
information is necessarily averaged across in this analysis.

CSF Tau and Aβ42 are Correlated with Specific Topographies of PET tau and Aβ
Penalized regression models (25-27) with either CSF tau or Aβ42 (separately)
as an outcome and regional PET tau and Aβ SUVR (together) as predictors were fit
to determine the relationship between CSF and regional PET measures. PET tau and
Aβ topographies were considered together in the model allowing for the data to
determine the modality that best predicted the variable of interest. The critical
feature of penalized regression is that the solution is sparse (i.e., the regression βs
corresponding to most PET tau and Aβ ROIs are set to zero) and only the most

predictive ROIs receive non-zero regression β weights. The relationship between
PET tau and Aβ topographies and CSF tau was examined first. The penalized model
significantly fit the data (R2 = 0.96; Z = 4.72; p < 0.0001). The combination of PET
tau and Aβ topographies that best correlate with CSF tau are shown in the top row
of Figure 4A (Exact values shown in Supplemental Table 3). CSF tau was equally
related to PET tau (

𝛽!"# = 2.93) and PET Aβ (

𝛽!" = 2.54), as measured by the

sum of the absolute value of the regression β values corresponding to PET tau and
Aβ ROIs, respectively. This equal weighting is consistent with tau pathology being
dependent on initial Aβ accumulation. Predictive PET tau regions include entorhinal
and temporal cortex and the cuneus. The PET Aβ contribution was derived from
temporal and frontal regions. Similar topographies of predictive PET regions of
interest were found when predicting CSF p-tau; the overall correlation between the
CSF tau and CSF p-tau predictive topographies was high (r = 0.77, p < 10-16).

Next, the same relationship was investigated but with CSF Aβ42 as the
predicted outcome variable. The penalized model significantly fit the data (R2 =
0.34; Z = 3.22; p =0.0006). The joint topographies of PET tau and Aβ that best
correlates with CSF Aβ42 are shown in the bottom row of Figure 4A (Exact values
shown in Supplemental Table 3). Most of the regression β values are negative owing
to the inverse relationship between CSF Aβ and pathology burden. In contrast to the
CSF tau model, the predictive weight is more skewed towards PET Aβ (
0.46) compared to PET tau (

𝛽!" =

𝛽!"# = 0.26). This suggests that PET tau has

relatively less predictive information relating to CSF Aβ42. The contributing
topography from PET tau was primarily loaded in the superior portions of the
cortex. The PET Aβ topography is composed primarily of frontal and parietal
regions. The highly significant predictive power of both models suggests that there
is a strong relationship between CSF and PET measures of tau and Aβ pathology.

Specific tau and Aβ Topographies Correlate with Neuropsychological Performance
To examine the relationship between pathology and cognitive function, the
relationship between PET tau and Aβ topographies and neuropsychological
composite scores was compared using the same penalized regression model as
described above. Each participant underwent neuropsychological testing that is
summarized into four composite scores summarizing the domains of episodic,
semantic, working memory, and visuospatial processing and an additional overall
(global) measure. Of these, episodic (Z = 2.42; p = 0.0078), semantic (Z = 4.85; p <
0.0001), visuospatial (Z = 5.17; p < 0.0001) and the global score (Z = 3.97; p <
0.0001) were significantly predicted by penalized regression after correction for
multiple comparisons while the working memory composite was not significantly fit
by the model. The combined PET tau and Aβ topographies that best predict each
cognitive composite are shown in Figure 4B (Exact values shown in Supplemental
Table 3). In each case, PET tau was the dominant topography with contributions to
the model, quantified as the sum of the absolute value of the regression β, two- to
nine-fold higher than the contribution of PET Aβ. With the exception of predicting
episodic memory, the topographies were sparse, including only temporal regions

and basal frontal regions. The overwhelming contribution of PET tau, specifically
temporal lobe tau, in each tested domain demonstrates that tau is more closely
related to cognition compared to Aβ.
We further investigated the correlation between PET tau and Aβ topography
and neuropsychological composite scores in the CDR 0 group only. In the domains
that were significantly associated with PET tau and Aβ topographies in the full
group, we refit the models in the CDR 0 group only and calculated the correlation
between the resulting predictive topographies. The topography that was predictive
of episodic memory scores in the full group was not correlated with predictive
topography in the CDR 0 group (r = 0.04, p = 0.70). Similarly, the topographies
predictive of semantic memory performance were not significantly correlated (r = –
0.01, r = 0.90). However, the topographies predicting visuospatial performance (r =
0.54, p <0.001) and global cognitive performance (r = 0.19, r = 0.091) were
correlated, albeit the latter at a trend level. These data suggest that the relationship
between pathology and neuropsychological performance varies over the course of
the disease.

Discussion
The present results identified topographies of tau deposition as measured by
T807 PET that were associated with clinical status, PET Aβ deposition, CSF AD
biomarkers, and AD-related cognitive impairment. A strong correlation existed
between Aβ deposited in one topography and tau deposited in another topography.
Tau imaging, both globally and in a specific topography, was significantly associated

with CSF measures of tau-related neural injury. In a combined model, PET tau
deposition was demonstrated to be more closely associated with cognitive function
than Aβ imaging. Together, these results establish tau imaging as a robust and
important biomarker of AD-related pathology.

The Aβ imaging literature is vast and has developed over more than a decade
(4), however tau imaging is a relatively new addition to the field. FDDNP was the
first tau imaging agent but had low signal to noise properties and also binds to Aβ,
which precluded investigation of specific pathological species (28) or required coimaging with Aβ agents and elaborate subtraction procedures (29). Methodological
studies (i.e., biochemistry and small animal studies) have identified several
compounds that are specific to tau pathology and possess favorable biochemical
properties (30, 31). Human studies have, to date, have been small (N<25) and
identified PET tau topographies consistent with post-mortem studies (20, 32-35). In
this preliminary body of work, PET tau pathology burden in specific regions of
interest (e.g., hippocampus) were more strongly correlated with cognitive
performance and hippocampal volume (34, 35). These studies have demonstrated
the utility of tau imaging agents in identifying tau pathology burden in vivo. The
present study builds on those studies by examining a larger cohort at various
disease stages and capitalizing upon the spatial information of PET by explicitly
relating tau topographies to disease stage, Aβ imaging, CSF biomarker, and
cognition.

PET tau and Aβ imaging acquires data at the resolution of approximately 5 to
8mm and sampled as many thousands of voxels, but the true dimensionality of the
data is likely much lower (36). This study identified two topographies for both PET
tau and Aβ that explained most of the variance in the data. The two tau topographies
were associated with disease severity as measured by the CDR. The first tau
topography was homogeneously distributed across the brain but the second was
concentrated in the temporal lobe. Similarly the first Aβ topography was broadly
distributed across the brain, while the second Aβ topography loaded more focally in
frontal and parietal regions and was significantly associated with disease stage.
Notably, the separation between CDR groups was visually more marked with
respect to tau burden (Figure 2B and C), though significant overlap remains. Overlap
with respect to CDR status likely represents the variable relationship between
pathological burden and cognitive symptoms often attributed to differences in host
factors, e.g., cognitive reserve (8, 23). This suggests that representation of
pathologically associated topographies of both tau and Aβ index disease progression
but the relationship to cognitive impairment is more pronounced with respect to
tau.

A unique feature of AD is that it is a dual proteinopathy. Indeed one of the
more debated mechanisms is how two pathological species progress in independent
topographies (11, 37, 38). While the topographies are distinct, this study uses
canonical correlation to emphasize that these two processes are related. In fact, the
correlation between tau and Aβ can be remarkably high when the relevant

topographies are considered. This suggests that, for a given severity of Aβ
deposition, the severity of tau pathology can also be estimated. The mechanism
underlying the relationship between Aβ and tau in the generation of AD is unclear,
but the empirical relationship is clearly evident.

In the absence of widely used tau PET ligands, CSF-based measurements of
tau pathology burden have predominated the AD field (39). CSF-based
measurements afford certain advantages (e.g., broad applicability) but do not
provide topographic information afforded by PET. Nevertheless, CSF-based
measures and PET-based measures index similar pathological processes in the
context of AD. As a result, a high correlation between mean PET tau SUVR and CSF
tau is expected. Perhaps less intuitive, but commonly observed, is the strong
relationship between CSF tau and PET Aβ SUVR, even in the absence of
neurofibrillary tangles (40). This relationship could be understood in terms of the
ordered nature of biomarker progression; once detectable tau pathology is present
there is already advanced Aβ pathology, allowing for a significant relationship (8, 9).
More importantly, the relationship between CSF and PET derived measures were
topographically specific. The specificity of this relationship strengthens the
argument that the identified relationships are disease specific: elevated tau in the
CSF is associated with tau deposition within regions known to be sensitive to ADrelated tauopathy (2). Taken together, these lines of evidence suggest that the
desired pathological process is being measured by both techniques.

Understanding the contribution of tau and Aβ to cognitive symptoms,
particularly early in AD, has been restricted owing to the lack of topographic tau
information in vivo. In this study, the predictive power of PET tau and Aβ
topographies on neuropsychological performance was evaluated. In each
investigated cognitive domain, the weight assigned to PET tau in the best fitting
model was larger than the weight assigned to PET Aβ. This implies that tau burden,
not Aβ burden, is more closely linked to cognition. This increased correlation
suggests that tau and cognition are more closely linked, consistent with extant
models of AD (8, 9). Further, PET imaging data coupled with the present penalized
regression approach also provides regional specificity. Temporal lobe tau tended to
be the strongest predictor of cognitive performance consistent with known focus of
tau pathology. The selective nature of the present models suggests that tauopathy
severity in the temporal lobe is sufficient to predict cognitive impairment across the
early disease stages investigated here.

Taken together, these data provide important insight into the relationship
between tau topographies and other measures of AD pathology and cognitive
symptoms. This inference is made possible by the emergence of PET tau imaging
agents. Tau imaging accurately discriminates disease stage assessed by the CDR,
strongly correlates with CSF measures, in particular within temporal regions, and is
more related to cognitive performance than Aβ imaging. Thus, tau pathology
appears to be more closely linked to cognitive dysfunction consistent with existing
hypotheses. These data suggest distinct roles of PET Aβ and tau imaging going

forward. PET Aβ will likely remain a powerful tool for early detection of AD
pathology during the preclinical period. However, these data suggest a close
relationship between PET tau and disease stage and symptomatology will be critical
for tracking the efficacy of disease modifying therapies.

Materials and Methods
Study Design
Forty-six participants were recruited from ongoing studies of memory and
aging at the Knight Alzheimer Disease Research Center at Washington University in
St Louis. Participants underwent cognitive assessment with the clinical dementia
rating (CDR) (19), MRI and PET imaging with T807 and Florbetapir. All participants
with CDR>0 (i.e., clinically impaired) carried clinical diagnoses of Alzheimer’s
disease or mild cognitive impairment due to Alzheimer’s disease. A subset of
participants also underwent lumbar puncture (N=36) and neuropsychological
assessment (N=40). All participants or their designees provided written informed
consent prior to participating in this study that was consistent with the regulations
of the Washington University in St Louis School of Medicine Institutional Review
Board.

Neuropsychological Assessment
A comprehensive neuropsychological battery was administered to all
participants, typically within two weeks of the annual clinical
assessment. Standardized test scores were averaged to form four composites [see

(41) for details on construction of composites and the standardization sample]. The
episodic memory composite included the sum of the three free recall trials from the
Selective Reminding Test (42), Associate Learning from the Wechsler Memory Scale
(WMS) (43), and immediate recall of the WMS Logical Memory or Wechsler Memory
Scale-Revised (WMS-R) (44) Logical Memory. The semantic composite included the
Information subtest from the Wechsler Adult Intelligence Scale (WAIS) (45), the
Boston Naming Test (46), and Animal Naming (46). The working memory
composite included WMS Mental Control, Digit Span Forward and Digit Span
Backward, and Letter Fluency for S and P. The visuospatial composite included the
WAIS Block Design and Digit Symbol subtests and Trailmaking Test A and B (47).

Imaging
MRI and florbetapir data were acquired on a Biograph mMR scanner
(Siemens Medical Solutions, Erlangen, Germany) in a single session. T807 data were
acquired in a separate session on a Biograph 40 PET/CT scanner. Participants
received a single intravenous (IV) bolus injection of 10 mCi of florbetapir and a
single IV bolus injection of 6.5-10 mCi of T807.
PET data were analyzed using our standard technique (18, 19) implemented
in the PET unified pipeline (http://github.com/ysu001/PUP). FreeSurfer
segmentation (44) (http://freesurfer.net/) was used as the basis of the quantitative
analysis to obtain regional standardized uptake value ratio (SUVR) with cerebellar
gray matter as the reference region. Partial volume correction was also performed
using a regional spread function (RSF) technique (19). For florbetapir PET, the data

between 50-70 minutes post-injection were used for the analysis; and for T807, the
imaging data between 80-100 minutes were used instead.

CSF Analysis
CSF (20-30 mL) was collected after overnight fasting as described previously
(48, 49). Total and phosphorylated tau and Aβ42 were measured using ELISA
(INNOTEST; Fujirebio, formerly Innogenetics, Ghent, Belgium).

Dimensionality Reduction and Analysis of a Single PET Modality
PET SUVR, for both T807 and Florbetapir, can be measured at the resolution
of voxels, structurally or functionally defined sets of voxels, or the entire brain. This
gives rise to datasets that appear to be high dimensional (i.e., many samples per
imaging session) but can be represented by lower dimensional projections. These
bases can be identified using singular value decomposition (SVD) or related
procedures (e.g., principal component analysis). In PET data, these composite
factors represent topographies (i.e., the weighted combination of brain regions) and
the contribution of a given topography to an individual participant’s data can be
estimated. SVD was performed on the regional SUVR values (as variables) across
participants (as samples) for tau and Aβ separately. The number of significant
factors was determined by a permutation test.

Identifying the Relationship Between Tau and Aβ Topographies and CSF and
Neuropsychological Performance Using Penalized Regression

Penalized regression was used to identify the relationship between CSF tau
and Aβ42 or neuropsychological Z scores, as outcome variables, and PET tau and Aβ
topographies (as predictors). The penalty in penalized regression is enforced
against the estimated regression βs (26). The family of penalized regression fit here
is the elastic-net penalty (27): the L1 penalty component enforces sparsity (i.e.,
many βs will be identically 0, not included in the model) (26) while the L2 penalty
allows highly correlated variables to enter the model simultaneously (27). Elasticnet models are well suited for data that are highly collinear such as regional PET
data. Model parameters (total penalty and relative contribution of L1 and L2
penalty) are chosen by cross-validation. Penalized regression models, like any
machine learning algorithm, are prone to overfitting. To assess significance of the fit
models, permutation resampling determined the distribution of R2 values under the
null hypothesis.

Canonical Correlation Identifies Relationships Between Tau and Aβ Topographies
Description of the correlation between tau and Aβ topographies is
accomplished using canonical correlation (50, 51). Canonical correlation is the
multivariate generalization of the more familiar, e.g., Pearson bivariate correlation.
Canonical correlation identifies the weighted average of ROIs in one distribution
that is maximally correlated with another weighted average of ROIs in another
distribution. The weighting vectors, or canonical vectors, define topographies.
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Table 1. Study Cohort Demographics.
T807 +
T807 +
T807 +
Florbetapir Florbetapir Florbetapir
+ CSF
+ NP
N
46
36
40
Age (standard 75.4 (6.6)
76.3 (6.6)
75.7 (6.5)
deviation)
M/F
30 / 16
25 / 11
27 / 13
CDR 0/0.5/≥1 36 / 7 / 3
31 / 2 / 3
34 / 4 / 2
APOE ε4+
20
16
18
Demographics for the main cohort and two subsets. CSF=cerebrospinal fluid assay,
NP= Neuropsychological Testing. APOE= apolipoprotein ε

Figures and Figure Captions

Figure 1. Mean positron emission tomography (PET) tau and Aβ topographies in
participants with and without clinical Alzheimer’s disease (AD). Mean tau SUVR
images averaged across participants with clinical dementia rating (CDR) 0 (top row)
or CDR>0 (bottom row). Images are presented in radiological convention.

Figure 2. PET tau and Aβ topographies are associated with disease severity. A: Right
singular vectors (𝑉) of the singular value decomposition (SVD) of the regional PET
tau and Aβ data represented as topographies. The dimensionality of both tau and Aβ
was estimated to be two. The first topography for both PET species broadly
represents the mean (i.e., all regions are homogeneously weighted). The second tau
topography is present within the temporal lobe and the second Aβ topography is
largely seen in frontal and parietal lobes. Color bar represents regional weights
within each singular component. B: The representations of these topographies in
individuals (left singular vectors; 𝑈), or put another way, the data original data
projected onto these topographies, varies with CDR for both PET tau topographies

and the second PET Aβ topography. Increasing disease severity (measured using the
CDR) is associated with increasing representation of the present topographies in
individuals. However, particularly in the Aβ data, there is significant heterogeneity.
C: Similar graphs as (B) but only participants with CSF are included. Color in the
CDR 0 group indicates preclinical disease status. Blue corresponds to healthy aging
(i.e., no Aβ or tau pathology), green corresponds to Stage 1, red corresponds to Stage
2.

Figure 3. Tau and Aβ in distinct topographies are strongly correlated. A:
Topographies for PET tau and PET Aβ derived from canonical correlations that
maximize the correlation between PET tau and Aβ deposition. B: Scatter plot of the
weights on each region demonstrates that PET tau and Aβ topographies are not

significantly related. This is consistent with the typical topographies of tau and Aβ
pathology being distinct. C: The data projected onto the canonical variables however
reveals a robust positive relationship.

Figure 4: CSF and Neuropsychological Performance are predicted by tau and Aβ
Topographies. Each row represents a single penalized regression model where
either CSF protein levels or neuropsychological performance is predicted.
and

𝛽!"#

𝛽!" represent the total predictive weight of tau and Aβ topographies,

respectively. Grey regions have no predictive weight. A: Penalized regression
models that predict CSF tau and Aβ42 using tau and Aβ topographies. As CSF Aβ42
levels are inversely related to amyloid burden, negative weights indicate regions
where topographies predict worse CSF Aβ42 pathology. B: Penalized regression

models that predict neuropsychological performance. Regions with negative values
are where more PET pathology predicts lower cognitive performance.

